Oxolife

Curated by Signal

Developer of embryonic implementation drug

Overview

Developer of an embryonic implementation drug. The company has developed a drug called OXO-001 for embryonic implementation and recovery ovulation in polycystic ovary syndrome to improve fertility in women.

Key facts

Founded: 2013
Headquarters: Barcelona, Spain
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

1 product or service: Sign up to view

Contact

Email: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Aniling
DNA sequencing solutions.
Life Sciences TechnologyBadalona, Spain
DevsHealth
Developer of therapeutics for infectious diseases
Life Sciences TechnologyBarcelona, Spain
Genomcore
Provider of a platform for personal genomic analysis
Life Sciences TechnologyEsplugues De Llobregat, Spain

About Oxolife

What does Oxolife do?

Developer of an embryonic implementation drug.

Where is Oxolife headquartered?

Oxolife is headquartered in Barcelona, Spain.

When was Oxolife founded?

Oxolife was founded in 2013.

Which sector is Oxolife in?

Oxolife operates in Life Sciences Technology.

Who are Oxolife's competitors?

Companies similar to Oxolife include Aniling, DevsHealth, and Genomcore.